stockrowAscendis Pharma A/S
ASND Healthcare Biotechnology
Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024.
- Revenue
- +119.9%
- EPS
- +612.3%
- Free cash flow
- +2,335.9%
- Total debt
- −41.8%
Quarter to June 2026, against a year earlier
Follow ASND
Alert me
Ascendis Pharma A/S (ASND) Revenue
Ascendis Pharma A/S's revenue for fiscal 2025 was $814.8M, up 107.1% from $393.5M in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.2B. Over the past ten years it has ranged from $1.7M (fiscal 2017) to $814.8M (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 5 consecutive fiscal years. Ascendis Pharma A/S ranks 21st of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $814.8M | 107.06% |
| FY2024 | $393.5M | 36.31% |
| FY2023 | $288.7M | 435.40% |
| FY2022 | $53.9M | 485.91% |
| FY2021 | $9.2M | 15.86% |
| FY2020 | $7.9M | (46.98%) |
| FY2019 | $15.0M | 19.88% |
| FY2018 | $12.5M | 622.57% |
| FY2017 | $1.7M | (66.07%) |
| FY2016 | $5.1M | (43.46%) |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $394.5M | 36.68% |
| Mar 2026 | $288.6M | 3.35% |
| Dec 2025 | $279.3M | 11.84% |
| Sep 2025 | $249.7M | 39.19% |
| 42 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. compare | $5.0B |
| JAZZ Jazz Pharmaceuticals PLC compare | $4.7B |
| BNTX BioNTech SE Sponsored ADR compare | $2.7B |
| EXEL Exelixis, Inc. compare | $2.5B |
| HALO Halozyme Therapeutics, Inc. compare | $1.8B |
| INSM Insmed, Inc. compare | $1.5B |
| ASND Ascendis Pharma A/S | $1.2B |
| BBIO BridgeBio Pharma, Inc. compare | $945.5M |
| SMMT Summit Therapeutics PLC compare | $705.0K |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on ASND
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement